Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kidney transplantation, the Halifax experience

P Belitsky1, A S MacDonald, J Lawen

  • 1Department of Urology, Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada.

Clinical Transplants
|January 1, 1996
PubMed
Summary

Canadian kidney transplant recipients benefit from improved graft survival with cyclosporine (CsA)-based immunosuppression. Key factors include HLA matching and managing chronic graft nephropathy, with older recipients and repeat transplants showing comparable outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pushing Photons with Electrons: Observation of the Polariton Drag Effect.

Physical review letters·2025
Same author

Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis.

Animal microbiome·2024
Same author

Time, momentum, and energy resolved pump-probe tunneling spectroscopy of two-dimensional electron systems.

Nature communications·2023
Same author

Impact of the COVID-19 pandemic on a post-mortem CT service for adult non-suspicious death.

Clinical radiology·2023
Same author

Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.

Nature communications·2023
Same author

Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.

Skin health and disease·2022

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Clinical Medicine

Background:

  • Canada lacks a national kidney sharing system, limiting cadaveric kidney sources.
  • Current recipient selection prioritizes HLA match and wait-list seniority, alongside ABO and crossmatch compatibility.
  • Cyclosporine (CsA)-based immunosuppression is standard, with antibody induction reserved for specific cases.

Purpose of the Study:

  • To evaluate graft and patient survival rates in Canadian kidney transplant recipients.
  • To identify key factors influencing graft survival, including HLA matching, immunosuppression protocols, and donor/recipient characteristics.
  • To assess the impact of specific challenges like chronic graft nephropathy, rejection, and prolonged cold ischemic time (CIT).

Main Methods:

Related Experiment Videos

  • Retrospective analysis of kidney transplant data within a defined Canadian region.
  • Comparison of graft survival rates based on HLA matching (especially HLA-DR), immunosuppression strategies (CsA, antibody induction), and donor type (cadaveric vs. live donor).
  • Evaluation of causes of graft loss, including acute and chronic rejection, and death with a functioning graft, stratified by recipient age and transplant history.

    • Main Results:

    • Zero HLA-DR mismatches significantly improve graft survival in first cadaveric transplants.
    • CsA-based immunosuppression yields graft and patient survival rates comparable to centers using antibody induction.
    • Chronic graft nephropathy remains the leading cause of graft loss post-first year, followed by death with a functioning graft.
    • Repeat cadaver transplant recipients achieve 5-year survival rates similar to first transplants.
    • Steroid-resistant rejection necessitates rescue therapy and leads to poorer long-term outcomes.
    • HLA-identical live-related donor transplants show improved long-term survival with CsA versus azathioprine.
    • Pre-transplant sensitization adversely affects haploidentical live-related transplants.
    • Patients over 60 demonstrate equivalent graft survival to younger recipients.
    • Prolonged CIT (>24 hours) is linked to increased ATN, dialysis, rejection, reduced QALYs, and higher costs.

    Conclusions:

    • Canadian kidney transplant outcomes are improving, particularly with CsA-based immunosuppression and attention to HLA matching.
    • Strategies to mitigate chronic graft nephropathy and optimize management of rejection are crucial for long-term success.
    • Age and repeat transplant status should not be absolute contraindications, while prolonged CIT requires careful consideration.